Cellular Intelligence, an AI drug startup backed by Mark Zuckerberg, said Monday that it has reached a “defining moment.” The Boston-based startup announced that it has acquired global rights to STEM-PD, an experimental Parkinson’s disease cell therapy program from Novo Nordisk, the Danish drugmaker best known for its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy. The deal gives Cellular Intelligence control of a clinical-stage therapy designed to restore the dopamine-producing nerve cells that are lost in Parkinson’s disease. The treatment uses stem cells from donors that are transformed into early-stage brain cells meant to become dopamine-producing neurons. It is currently being tested in a first-in-human Phase 1/2 clinical trial and has received FDA Fast Track Designation. Cellular Intelligence now plans to use its AI platform to push the treatment through further clinical development, manufacturing, and, if successful, commercialization.…